Achondroplasia: cross-border specialty drug access for international patients

Quick orientation

Achondroplasia affects approximately 1 in 25,000 live births worldwide and is the most common form of disproportionate short stature. The condition is caused by a gain-of-function variant in the FGFR3 gene.

Typical age of onset. Congenital. Diagnosis is typically confirmed at birth or in early infancy on the basis of characteristic skeletal features and radiographic findings, with molecular confirmation available.

Severity tiers. Severity is generally uniform clinically, although spinal complications such as foramen magnum stenosis and thoracolumbar kyphosis can be life-threatening in a small minority of infants and warrant early surveillance.

Why specialty drugs for Achondroplasia are hard to access internationally

Voxzogo (vosoritide) became the first targeted therapy approved by the FDA for achondroplasia in 2021. It remains unregistered in many MENA and South Asian markets, and where it is registered, payer coverage and supply continuity vary year to year. The drug is dosed by body weight and requires daily subcutaneous injection, which means international families need to coordinate refrigerated supply, pediatric titration, and growth monitoring with a treating endocrinologist or clinical geneticist before they ever place an order.

Treatments approved by the FDA

• Voxzogo (vosoritide) — FDA approval: 2021. Mechanism: C-type natriuretic peptide analog that stimulates endochondral bone growth. Route: Daily subcutaneous injection. US WAC ballpark: Approximately USD 320,000 per year. Country pricing: Egypt · Bahrain · Oman · Lebanon.

Cross-border pathways used for Achondroplasia

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Compassionate Use
• Expanded Access Program (EAP)
• Personal Import Scheme

What your physician needs to know

• Vosoritide is approved by the FDA for children aged 5 years and older whose epiphyses are not closed.
• Treatment requires baseline and serial growth velocity assessment, bone age x-ray, and ECG monitoring.
• Dose is weight-based; families crossing borders need supply continuity planning before initiation.
• Cold chain at 2 to 8 degrees Celsius must be preserved from US dispense through destination delivery.
• Coordinate with a pediatric endocrinologist or clinical geneticist familiar with skeletal dysplasias.
• Foramen magnum and craniocervical junction imaging is part of the baseline workup for many specialist centers.

Common questions

Is Voxzogo available in my country?

Registration status varies by country. As of late 2025 Voxzogo is approved in the United States, the European Union, the United Kingdom, Japan, and Australia. In most MENA, South Asian, and African markets it is either unregistered or pending review. Reserve Meds confirms current status for your specific destination.

Can my child start vosoritide before age 5?

The FDA label is for children aged 5 years and older. Some compassionate-use programs have considered earlier initiation in specific cases; this requires a direct request from the treating physician with supporting clinical rationale.

Does Reserve Meds dispense Voxzogo?

We coordinate cross-border access through Named Patient Programs and related pathways. The drug is dispensed by a US-licensed pharmacy after a US-licensed physician has reviewed the request and your prescribing physician has issued the prescription.

How is the cold chain handled?

Shipments use validated specialty couriers with continuous temperature monitoring. We provide chain-of-custody documentation on delivery.

What happens if my child gains weight and the dose needs to change?

Re-dosing intervals follow the label. Your endocrinologist updates the prescription; Reserve Meds adjusts the next shipment quantity accordingly.

What documents do I need to start a request?

A current pediatric clinical summary, growth chart, genetic confirmation if available, and a prescription from a treating physician. Reserve Meds confirms what your destination country requires.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Achondroplasia, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Achondroplasia

Reserved for you.